Clinical Trial Update: A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HRS-4642 in combination with nab-paclitaxel and gemcitabine as conversion therapy for locally advanced pancreatic cancer with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)
• HRS-4642

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Locally Advanced Pancreatic Cancer With KRAS G12D Mutation | Phase 2 | Status: RECRUITING